Hologic's (HOLX) Hold Rating Reiterated at Needham & Company LLC

Key Points

• Hologic's stock maintained a "hold" rating from Needham & Company LLC, while Citigroup upgraded it to a "buy" rating with a price target raised from $60 to $80.
• Hologic reported better-than-expected quarterly earnings, with EPS of $1.08, surpassing analysts' estimates of $1.05.
• A significant insider transaction occurred when CEO Stephen P. Macmillan sold over 138,000 shares, reducing his stake by 10.08% at an average price of $66.97.

Hologic (NASDAQ:HOLX - Get Free Report)'s stock had its "hold" rating restated by analysts at Needham & Company LLC in a report issued on Tuesday,Benzinga reports.

A number of other brokerages also recently weighed in on HOLX. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research report on Wednesday, October 1st. Evercore ISI set a $78.00 price objective on Hologic and gave the stock an "outperform" rating in a research note on Tuesday, October 7th. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and raised their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Hologic in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $80.15.

Hologic Stock Up 3.2%

NASDAQ HOLX traded up $2.30 during mid-day trading on Tuesday, reaching $74.17. 11,655,631 shares of the company's stock traded hands, compared to its average volume of 2,655,833. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic has a 1-year low of $51.90 and a 1-year high of $84.39. The company has a fifty day simple moving average of $67.19 and a 200-day simple moving average of $63.62. The company has a market cap of $16.50 billion, a price-to-earnings ratio of 30.77, a P/E/G ratio of 2.40 and a beta of 0.63.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts expect that Hologic will post 4.28 EPS for the current year.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.88% of the company's stock.

Institutional Trading of Hologic

A number of hedge funds have recently bought and sold shares of the company. Chung Wu Investment Group LLC purchased a new stake in shares of Hologic in the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock worth $27,000 after buying an additional 273 shares during the period. Loomis Sayles & Co. L P purchased a new position in shares of Hologic during the second quarter valued at $33,000. Zions Bancorporation National Association UT purchased a new stake in Hologic in the 1st quarter worth about $34,000. Finally, Cromwell Holdings LLC boosted its position in Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock worth $38,000 after acquiring an additional 436 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.